Interpace Diagnostics Group, Inc. (IDXG)
| Previous close | 1.4700 |
| Open | 1.3700 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 1.4700 - 1.4700 |
| 52-week range | 0.6203 - 3.5400 |
| Volume | |
| Avg. volume | 5,704 |
| Market cap | 6.433M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 5.88 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and 119% increase year-over-year ●Q4 and FY Adjusted EBITDA of $1.5 million and $5.4 million; a $6.6 million and 463% increase year-over-year ●Q4 and FY Cash collections of $10.2 million and $40.4 million; a $9.0 million and 29% increase year-over-year ●Q4 and FY Volume, Revenue, and Profitability at al
- GlobeNewswire
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. Third quarter Net Revenue was
